Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 1/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.35 |
| ▸ | DPP4 | P27487 | 3/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 5/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | INSR | P06213 | 1/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15876876 | 0.87 | TSPO (0.42) | TSPODPP4EGFRFYNKDR | |
| SCHEMBL16212933 | 0.85 | KDM4E (0.41) | TSPOEPHB4DPP4SCN9AFYN | |
| SCHEMBL643970 | 0.84 | FLT1 (0.39) | TSPOEGFRFYNKDRERBB2 | |
| SCHEMBL27532 | 0.83 | FYN (0.43) | TSPOEPHB4EGFRFYNKDR | |
| SCHEMBL29714497 | 0.83 | FYN (0.43) | TSPOEPHB4EGFRFYNKDR | |
| SCHEMBL16212409 | 0.81 | TSPO (0.38) | TSPOEPHB4EGFRFYNABCG2 | |
| SCHEMBL29229255 | 0.79 | TP53 (0.48) | EPHB4EGFRFYNKDRERBB2 | |
| SCHEMBL30505593 | 0.79 | TP53 (0.48) | EPHB4EGFRFYNKDRERBB2 | |
| SCHEMBL16212573 | 0.79 | DHFR (0.40) | TSPOEPHB4DPP4EGFRFYN | |
| SCHEMBL15877127 | 0.79 | DHFR (0.40) | TSPOSCN9AEGFRADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623883-B2 | 4-phenylamino-quinazolin-6-yl-amides | WARNER-LAMBERT COMPANY LLC (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130274275-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | WARNER-LAMBERT COMPANY LLC | 2013-10-17 | — | — | US | disclosed |
| US-8466165-B2 | 4-phenylamino-quinazolin-6-yl-amides | WARNER-LAMBERT COMPANY LLC (US) | 2013-06-18 | — | — | US | disclosed |
| EP-1746999-B1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | WARNER LAMBERT CO (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110262877-A1 | HEAT TREATMENT APPARATUS | IHI CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| US-7772243-B2 | 4-phenylamino-quinazolin-6-yl-amides | WARNER-LAMBERT COMPANY LLC (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100190977-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | PFIZER INC. | 2010-07-29 | — | — | US | disclosed |
| EP-1746999-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | Warner-Lambert Company LLC (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005107758-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050250761-A1 | such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190977-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | HRH4, HRH3, HRH2 | TSPO 3248/4885EPHB4 3098/4885DPP4 3294/4885 |
| US-20050250761-A1 | such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis | JAK1, JAK2, EDNRA | TSPO 2408/4885EPHB4 682/4885DPP4 3625/4885 |
| US-20130274275-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | HRH4, HRH3, HRH2 | TSPO 3248/4885EPHB4 3098/4885DPP4 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.